← Human Trials & Peer-Reviewed Studies
Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial
Plain-language guide to PMID 20656516 (2011): double-blind randomized controlled trial study of Cerebrolysin in 242 patients.
Key Facts
- PMID
- 20656516
- Journal
- Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Guekht AB et al. (4 authors)
- DOI
- 10.1016/j.jstrokecerebrovasdis.2010.01.012
- Registered trial
- NCT00947531
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Cerebrolysin.
The researchers conducted a large, multicenter, double-blind, placebo-controlled study in 242 patients meeting the criteria for VaD.
The primary endpoint was the combined outcome of cognition (based on Alzheimer's Disease Assessment Scale Cognitive Subpart, Extended Version [ADAS-cog+] score) and overall clinical functioning (based on Clinician's Interview-Based Impression of Change plus Caregiver Input [CIBIC+] score) assessed after 24 weeks of treatment.
Who Took Part
The study group was 242 patients.
The age groups tagged for this paper are middle-aged adults and older adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind, placebo-controlled and multicenter study.
Because people in this Cerebrolysin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the patients and researchers unaware of who received Cerebrolysin.
A placebo (an inactive look-alike) gave the Cerebrolysin group a baseline to be compared against.
More than one site took part, so the patients came from several places.
The methods mention a period of 24 weeks.
What Was Measured
The primary endpoint was the combined outcome of cognition (based on Alzheimer's Disease Assessment Scale Cognitive Subpart, Extended Version [ADAS-cog+] score) and overall clinical functioning (based on Clinician's Interview-Based Impression of Change plus Caregiver Input [CIBIC+] score) assessed after 24 weeks of treatment.
PubMed files the paper under topics including Amino Acids, Aspirin, Chi-Square Distribution, Cognition, Dementia, Vascular, Europe and Logistic Models.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Cerebrolysin in 242 patients over 24 weeks.
The publication is from 2011 (Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association), a journal based in United States.
More context: the Cerebrolysin compound page.
Our Notes on the Compound
Cerebrolysin: A mixed neurotrophic preparation (NGF-, BDNF-, GDNF- and CNTF-like activity).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.